News

Contribute towards the global effort to combat antibiotic resistance.

Allecra has one product candidate in Phase 1 clinical trials and another more advanced product candidate in Phase 2 trials. Each of Allecra’s two product candidates is designed to have a unique spectrum of activity and is clearly differentiated from current treatment options and from competitors’ development pipelines

Allecra Therapeutics Announces New Staged Financing Deal to Take the Company Through to End of Phase 3

Funding supports clinical development up to registration of Allecra’s novel antibiotic to treat resistant Gram-negative bacterial infections in hospitals Lörrach, Germany and Saint Louis, France– Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics forthe treatment of drug-resistant bacterial infections, announces today the initial closing of a staged financing deal designed to…

Find out more

Allecra Announces Initiation of a Phase 2 Clinical Trial for its Novel Antibiotic to Treat Resistant Bacterial Infections

Allecra’s novel β-lactamase inhibitor AAI101, co-administered with the powerful β-lactam cefepime, is to be evaluated in patients for its potential to combat hospital-acquired, resistant Gram-negative infections Lörrach, Germany and Saint Louis, France – Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, today announces initiation of a…

Find out more

Allecra Therapeutics Strengthens Leadership Team with Appointment of New Chairman and Chief Medical Officer

Lörrach, Germany and Saint Louis, France – Allecra Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, announced today two key appointments to significantly strengthen Allecra’s leadership team as the Company enters its next phase of development. Dr. Engelbert (Bert) Tjeenk Willink is appointed to the position…

Find out more

Allecra Therapeutics Announces €22 Million Series B Financing

Funding Supports Phase 2 Development of Novel Antibiotic to Treat Resistant Gram-negative Bacterial Infections in the Hospital Lörrach, Germany and Saint Louis, France – Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, announced today the closing of its €22 Million Series B investment round. The round…

Find out more
""